The Syn-One Test Reports High Sensitivity and Specificity Across Multiple Synucleinopathies.

Published Date: 04 May 2023

The sensitivity rates for the -synuclein skin biopsy test developed by CND Life Sciences ranged from 92.7% to 100% for a variety of synucleinopathies that were evaluated and clinically confirmed, including Parkinson disease and dementia with Lewy bodies, among others.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast Cancer Patients Living Longer Post-Medicaid Expansion

2.

Error on the MGUS-Autoimmune Disease Association.

3.

Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.

4.

The majority of cancer medications that receive expedited approval end up failing confirmatory trials.

5.

Unified Neuro/Psych Residency Program: New Proposal.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot